Parkinson disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• APOE 1
• TNF 0
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• STAT3 0
• TREM2 0
• HDAC 0
• JAK 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 28+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  High-Dose Ambroxol in GBA1-Related Parkinson

  NCT06193421· Agyany Pharma LTD· Updated 9 Nov 2026

  “Sponsor's decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

  NCT07011771· Capsida Biotherapeutics, Inc.· Updated 22 Jun 2026

  “Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Parkinson's Disease in Type 1 Gaucher Disease

  NCT07886879· Icahn School of Medicine at Mount Sinai· Source

• Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

  NCT06993142· Radboud University Medical Center· Source

• Ambroxol as a Disease-modifying Treatment in GBA-PD

  NCT05287503· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease

  NCT04668898· Icahn School of Medicine at Mount Sinai· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 75
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 34
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 100
• Magnetic Resonance Imaging 366
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 184
• Genome-Wide Association Study 83

See which targets of this disease your abstract mentions, and go to the people working on them.